Thelansis Crohn’s disease (CD) is a chronic disorder characterized by exacerbations and periods of remission that cause inflammation of the gastrointestinal (GI) tract. Although it can involve any area of the GI tract, it most commonly affects the small intestine and/or colon. Crohn’s disease and ulcerative colitis are the two main diseases among a group of illnesses called inflammatory bowel disease (IBD). The symptoms of these two diseases are very similar, so it is sometimes difficult to establish a definitive diagnosis. One difference, however, is that ulcerative colitis affects only the colon, while Crohn’s disease may affect any part of the GI tract and often affects the end of the small bowel (the ileum) and the beginning of the colon.
Thelansis "Crohn’s disease (CD) – Market Insight and Landscape report 2015 - 2030" report provides the detailed therapy area landscape comprises of disease overview, pathogenesis, biomarker specific patient population, country/region specific current treatment practice and market landscape. Half of all CD cases involve the ileum and colon and in 25% of cases, only the colon is affected. Approximately 15% of colitis cases are called indeterminate colitis because they cannot be classified as either ulcerative colitis or Crohn’s disease.
According to Thelansis the global Crohn’s disease (CD) market was estimated at ~$5,425 MN in 2015 and expected to reach at ~$ 12,346 MN by the end of 2030 (15 years of markets projections; four years of historical data, current and eleven years of future market projections). They attribute the high growth to the launches of biologics and biosimilars of Humira, Cimzia, and Tysabri and increased uptake of Remicade and Entocort.
A population-based study the total number of new cases of Crohn’s disease diagnosed each year (incidence) was 10.7 per 100,000 people or approximately 34,976 new cases per year, however, the number of new cases of ulcerative colitis diagnosed each year was ~41,250 new cases per year
Epidemiology and patient segmentation:
According to Thelansis, globally ~ 2.3 MN patients are being diagnosed with Crohn’s disease (CD) in 2015 among which 8MM countries are comprised of ~75% of the total yearly reported cases. The total current market of Crohn’s disease is $ 3,821 MN in 2015 and expected to reach at ~$ 12,049 MN by the end of 2030(15 years of markets projections; four years of historical data, current and eleven years of future epidemiology projections). Considering the country level perspective the USA and EU5 are contributing around ~73% of the total diagnosed patient pool, however, in terms of market USA is leading considering the current disease burden and treatment cost. Diagnosed incidence trends are relatively high in the USA, EU5 and Japan attributed to the early screening programs and the diagnosis of the patients in the early stages of the disease
Crohn’s disease - biomarker level patient segmentation:
Molecular epidemiology study of specific biomarker mutations across country level has been given a clear understanding on patient pool across different biomarker targets (TNF-alpha, CARD15, IBD5, ATG16L1, IRGM, interleukins, and another inflammatory cytokine)
One goal of medical therapy is to suppress the inflammatory response, thereby allowing the intestinal tissue to heal, and also relieving symptoms of fever, diarrhea, and abdominal pain. Medications are also used to reduce the frequency of disease flares.
There are five categories of drugs used to treat Crohn’s disease:
• Aminosalicylates (5-ASA)
• Immune modifiers
• Biologic therapies (Infliximab, Adalimumab, Natalizumab, Certolizumab pegol, etc.)
As many as 75% of Crohn’s disease patients required at least one surgical procedure during their lives, most often due to lack of response to medical therapy. Additional indications for surgery include intra-abdominal abscess, massive bleeding, symptomatic refractory internal or perianal fistulas, and intestinal obstruction. The overall goal of surgery in Crohn’s disease is to conserve bowel function and return the individual to the best possible quality of life. Continued use of medications is necessary to minimize the risk of recurrences.
As per Thelansis, based on tumor mutation evidence some of key player are into developing therapies for the treatment of Crohn’s disease such as: Celgene, Gilead Sciences, Otsuka, Galapagos, J&J, AbbVie, Boehringer Ingelheim, Allergan, UCB, Elan Pharmaceuticals, Biogen, Shire, Mitsubishi, Fast Forward, Roche, Amgen, Qu Biologics, AstraZeneca, Theravance Biopharma, GSK, Valeant Pharmaceuticals, Novartis, Landos Biopharma, Eli Lilly, Reistone Biopharma, Provention Bio, Pfizer, BMS
The annual cost of therapy:
According to the published literature review, Crohn’s disease is one of the most prevalent diseases in the United States including other developed and developing nations. For patients with CD, the yearly cost burden ranges from $2,952 to $20,928 includes all hospitalization and non-hospitalization cost.
Pharmaceutical therapy claims accounted for the largest proportion of direct costs (41.3%) among which TNF alpha was the most costly medication; approximately 10% of patients with CD had at least 2 claims for infliximab infusions. Hospitalization and outpatient services accounted for around 32.5% and 34.1%, respectively
Emerging therapies ultimately need to demonstrate efficacy on long-term clinical outcomes in the patients diagnosed with moderate to severe stage of Crohn’s disease currently on biologics or any other form of targeted therapy
More than 55% of the disease population diagnosed in their later stage of the disease, so the awareness around diagnosis procedure and technology need to be spread around to maximize the early diagnosis
Multiple targets need to be identified and targeted to get control on the quality of life of the patients
From the payer’s perspective majorly focused on cost savings as both at public and private payer entities are seeking methods to reduce Crohn’s disease-related expenditures. The treatment of Crohn’s disease has changed dramatically since the launch of biosimilars of many TNF alpha biologics. Screening has and will continue to increase cure rates. Molecular profiling, coupled with biosimilars version of targeted therapies and the expanding role of immunotherapy, is becoming so effective and justifiably that the cost saving has been going up at each passing day.
The European nations regulatory bodies and payers are having a very positive mindset with respect to the approval and access of biosimilars, which will bring the country level disease burden as well as the treatment cost in coming years. Apart from cost, payers have also concerned the continuous recommendation of services (e.g., therapies or diagnostic tests) that have not demonstrated improvements in the outcomes that matter to patients.
About the company
As the name depicts Thelansis is specialized in “Therapy Landscape Analysis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook, and Market Access Reports. Our focused therapeutic approach provides our clients with clinical and disease area expertise from an integrated team of academic, medical, and industry specialists of our panel, Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at, [email protected]
Thelansis Knowledge Partners
183 Asylum Street Hartford, CT-06103, US
USA +1 (302) 380-3552
Thelansis Knowledge Partners
C Wing Vrindavan tech village
Marathahalli Outer ring road